Research Awards: October 2010
Cannon-McCullough, Carolyn, Univ. of Akron/ NIH, Collaborative Research: Polymeric Drug Delivery Systems and Biofilms in the Lung - ARRA Stimulus Admin Supplemental, $15,850; Carr, Bruce, NIH, Contraceptive Efficacy Evaluation of Path Female Condom, $115,866; Chan, Roger, McGill Univ./NIH, Design, Construction and Evaluation of Implants for Vocal Fold Alteration and Reconstruction, $92,260; Clegg, Deborah, Purdue Univ./NIH, Energy Dysregulation: Behavioral and Biological Signals, $24,870; Diaz-Arrastia, Ramon, U.S. Dept. of Education, North Texas Traumatic Brain Injury Model Systems, $430,350.
Dowling, Michael, Univ. of Calif., San Francisco/NIH, Vascular Effects of Infection in Pediatric Stroke: VIPS, $18,369; Dowling, Michael, Washington Univ., St. Louis/NIH, Silent Cerebral Infarction Multicenter Clinical Trial - Neurology Committee, $3,959; Falck, J. Russell, Medical College of Wisconsin/NIH, Cytochrome P450 Eicosanoids and Myocardial Injury, $23,578; Goldberg, Mark, Washington Univ., St. Louis/NIH, Cell-Cell Interaction and Hypoxic Brain Injury, $237,818; Goodman, Joel, Columbia Univ./NIH, Summer Immunology Research Program for High School Science Teachers, $30,204.
Gruchalla, Rebecca, Univ. of Wisconsin/NIH, Inner City Asthma Consortium (ICAC): Immunologic Approaches to Reduce Asthma, $562,060; He, Yu-Guang, Emmes Corp./NIH, Age-Related Eye Disease Study 2 (AREDS2), $4,104; Journeycake, Janna, UT Health Science Center at Houston/NIH, Region VI Comprehensive Hemophilia Center, $39,061; Lehrman, Mark, Sanford-Burnham Medical Research Inst./NIH, Testing Substrate-Flux Therapies for Glycosylation Disorders Using Zebrafish - ARRA Stimulus Challenge Grant, $111,642; Mason, Ralph, UT Arlington/NIH, Enabling Aliphatic Biodegradable Photoluminescent Polymeric Biomaterials, $39,338.
Miller, David, Gynecologic Oncology Group/NIH, Gynecologic Oncology Group Studies, $2,020; Niederkorn, Jerry, Baylor College of Medicine/NIH, Environmentally-Induced Ocular Surface Inflammation Mimicking Sjogren’s Syndrome - ARRA Stimulus Funding, $47,100; Patridge, Emily, Houston Academy of Medicine/NIH, Outreach and Promotion of MedlinePlus to Underserved and Underrepresented Minority High School Students and Families in Dallas, $6,500; Rutherford, Cynthia, UT Health Science Center at Houston/NIH, Region VI Comprehensive Hemophilia Program, $39,127; Sanchez, Pablo, RTI International/NIH, NICHD Cooperative Multicenter Neonatal Research Network, $8,289.
Scheuermann, Richard, Northrop Grumman Corp./HHSN, Bioinformatics Resource Center for Infectious Diseases (BRC), $520,554; Shay, Jerry (Mak, S., fellow), U.S. Dept. of Defense, Structural and Dynamic Elucidation of Telomeric Ends: Novel Approach to Breast Cancer Therapeutics, $32,400; Shay, Jerry (Chow, T., fellow), U.S. Dept. of Defense, Manipulating Telomere Overhand Processing to Develop Novel Approaches for Breast Cancer Treatment, $32,400; Sherry, A. Dean, Duke Univ. Medical Center/NIH, Development of Novel Therapies for NIDDM: Targeted Responsive MR and PET Agents for B-Cell Imaging, $106,378; Siegel, Jane, Dallas County Hospital District/CDC, MRSA Colonization and Control in Dallas County Jail, $29,125.
Tamminga, Carol, Univ. of Maryland/NIH, Bipolar-Schizophrenia Network for Immediate Phenotypes, $18,400; Timmerman, Robert, American College of Radiology/NIH, Radiation Therapy Oncology Group (RTOG), $12,150; Trivedi, Madhukar, NIH, Clinical Trial Network: North Texas Node - Year 06 Supplements, $1,550,000; Vusirikala, Madhuri, Natl. Marrow Donor Program/NIH, RDSafe: Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life, $2,000.
Wang, Junmei, Univ. of Calif., Davis, Medical Center/NIH, AMBER Force Field Consortium: Coherent Biomolecular Simulation Platform, $70,000; Willson, James, U.S. Dept. of Defense, Nanotechnology in Cellular Therapies, $1,022,000; Winick, Naomi, Natl. Childhood Cancer Fndtn./NIH, COG Phase 1 Pilot Consortium; #20171, $27,866; Yanagisawa, Masashi, Mount Sinai School of Medicine/NIH, Neural Substrates of Appetitive Behavior in Mood and Motivation - Project III, $61,858.
Auchus, Richard, Cornell Univ./Partnership for Clean Competition, Characterization of Human Urinary Steriodome for Antidoping Applications, $72,649; Hooper, Lora (Vaishnava, S., fellow), Crohn's & Colitis Fndtn., Paneth Cell Specific Innate Immune Response to Intestinal Bacteria, $45,750; Iannaccone, Susan, Wayne State Univ./Muscular Dystrophy Assn., North American CMT Network, $11,000; Liu, Li, Baylor College of Medicine/CPRIT, Investigation of Highly Potent Benzosuberene Analogs as Novel Anticancer Agents, $31,578; Lu, Q. Richard, Natl. Multiple Sclerosis Society, Zfp488 in Oligodendrocyte Differentiation, $154,377.
Monson, Nancy, Natl. Multiple Sclerosis Society, Molecular Analysis of Ig Repertoire in MS, $160,129; Olson, Eric, Fondation Leducq, Micro RNAs as Therapeutic Targets in Heart Failure, $254,485; Parada, Luis, Simons Fndtn., Mouse Models of Human ASDs: Gene Targeting in Specific Brain Regions, $400,000; Pfeiffer, Julie, American Cancer Society, Ribavirin Uptake as Determinant of HCV Treatment Response, $178,420.
Rosen, Michael (Chen, Z., fellow), Cancer Research Inst., Inhibition and Activation Mechanisms of WAVE Regulatory Complex, $48,500; Savani, Rashmin, IKARIA, Educational Lecture Series in Neonatal-Perinatal Medicine, $5,600; Taurog, Joel, U.S.-Israel Binational Science Fndtn., Sequence Analysis of Peptides Bound to HLA-B27 in Patients and Transgenic Rats with Spondyloarthritis, $25,000; Wiebe, Deborah (Croom , A., fellow), Timberlawn Fndtn., Illness Perceptions of Patients With Advance Stage Cancer and Their Partners, $14,000.
Industry-Sponsored Awards, dollar amounts not available
Byerly, Matthew, 24-Week, Flexible-Dose, Open-Label Extn Study of Subjects Switched to Lurasidone for Trtmt of Schizophrenia or Schizoaffective Disorder; Byerly, Matthew, Rand, 6-Week, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lurasidone for Trtmt of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents; Chin, Kelly, Registry to PROSPECTively Describe Use of Epoprostenol for Injection (“RTS Epoprostenol”) in Patients With Pulmonary Arterial Hypertension.
Diaz-Arrastia, Ramon, Open-Label, Non-Random Study to Evaluate Efficacy and Safety of BAY 94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral ß-amyloid When Compared to Post Mortem Histopathology; DiMaio, Michael, Evaluation of Clinical PeRformancE of Valiant Thoracic Stent Graft With Captiva Delivery System for EndovaSCUlar trEatment of Blunt Thoracic Aortic Injuries (RESCUE); Joglar, Jose, BENEFIT: Risk Stratification & Benefits with CRT Therapy.
Khera, Amit, Multicenter Random Double-Blind Placebo-Controlled Cardiovascular Outcomes Study to Evaluate Potential of Aleglitazar to Reduce Cardiovascular Risk in Pts With Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus; Kurian, Benji, 4-Week, Random Double-Blind Parallel-Group, Plcebo-Controlled Study to Investigate Safety and Efficacy of EVT 101 as Monotherapy in Patients With Treatment-Resistant Major Depression; Kurian, Benji, Random Phase 2A, Double-Blind, Plcebo-Controlled Study of Efficacy and Safety of CP-601,927 Augmentation of Antidepressant Therapy in Major Depression.
McCulley, James, Study Coordinator Agreement; Miller, David, Open-Label, Single-Arm, Multicenter Phase 2 Study of E7080 in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy; Raskin, Philip, Phase II, Random, Double-Blind, 2-Way Crossover Safety and Efficacy Study of Subcutaneously Injected Prandial Insulins: Lispro-PH20 or Aspart-PH20 Compared to Insulin Lispro (Humalog®) in Patients With Type 1 Diabetes; Raskin, Philip, Phase II, Random, Double-Blind, 2-Way Crossover Safety and Efficacy Study of Subcutaneously Injected Prandial Insulins: Lispro-PH20 or Aspart-PH20 Compared to Insulin Lispro (Humalog) in Patients With Type 2 Diabetes.